• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[作为潜在疫苗株选择指标的耐药染色体标记]

[Chromosome markers of drug resistance as the selectors of potential vaccinal strains].

作者信息

Bondarenko V M, Marakusha B I

出版信息

Antibiotiki. 1984 Feb;29(2):124-6.

PMID:6367629
Abstract

Mutations resulting in acquisition of the resistance to rifampicin, streptomycin, neamine, polymyxin M, mecillinam and high concentrations of nalidixic acid were studied with respect to their effect on virulence of Shigella flexneri by transduction of the markers from the spontaneous avirulent mutants to the initial strain. It was shown that the acquisition of the determinants of the resistance to rifampicin, streptomycin, neamine (nea A) and high concentration of nalidixic acid resulted in 100 per cent of the cases in losing the transductant capacity for causing keratoconjunctivitis in guinea-pigs. With the mutations resulting in the acquisition of resistance to neamine (nea B) and mecillinam virulence was lost only in a part of the clones (33 and 53 per cent respectively). The changes in the pathogenic properties of the transductants with the acquired markers of the resistance to the above antibiotics were associated with impairment of the bacterial cell vital structures. It is suggested that the genetically characterized avirulen immunogenetic mutants be used as potential vaccinal strains.

摘要

通过将自发无毒突变体的标记物转导至初始菌株,研究了导致对利福平、链霉素、新霉素、多粘菌素M、美西林和高浓度萘啶酸产生抗性的突变对福氏志贺氏菌毒力的影响。结果表明,获得对利福平、链霉素、新霉素(nea A)和高浓度萘啶酸的抗性决定簇后,100%的转导子丧失了在豚鼠中引起角结膜炎的能力。对于导致对新霉素(nea B)和美西林产生抗性的突变,仅部分克隆(分别为33%和53%)丧失了毒力。具有上述抗生素抗性获得性标记的转导子致病特性的变化与细菌细胞重要结构的损伤有关。建议将经基因鉴定的无毒免疫遗传突变体用作潜在的疫苗菌株。

相似文献

1
[Chromosome markers of drug resistance as the selectors of potential vaccinal strains].[作为潜在疫苗株选择指标的耐药染色体标记]
Antibiotiki. 1984 Feb;29(2):124-6.
2
[Isolation and characteristics of polymyxin-resistant mutants of Shigella flexneri].[福氏志贺菌多粘菌素抗性突变体的分离与特性]
Antibiotiki. 1980 Oct;25(10):753-8.
3
[High-immunogenic mutants of Salmonella with two independently of each other attenuating markers as potential vaccines from bacteria capable of multiplication. 2. Communication: spontaneous chromosomal resistance against antibiotics as a possibility for isolation of clones with decreased virulence (author's transl)].[具有两个相互独立的减毒标记的高免疫原性沙门氏菌突变体作为来自能够增殖的细菌的潜在疫苗。2. 通讯:自发染色体抗生素抗性作为分离毒力降低的克隆的一种可能性(作者译)]
Zentralbl Bakteriol A. 1981 Aug;249(3):350-61.
4
[Basic approach to the production of potential vaccine strains of Salmonella, Shigella and Pasteurella, capable of reproduction, using suitable genetic markers].
Z Gesamte Hyg. 1984 Mar;30(3):141-7.
5
[Genetic mapping of the mitochondrial markers of antibiotic resistance in PG-strain Saccharomyces cerevisiae yeasts].[酿酒酵母PG菌株中抗生素抗性线粒体标记的遗传图谱分析]
Genetika. 1982 Jul;18(7):1067-74.
6
[An analysis of the plasmid profile of Shigella flexneri strains used for obtaining vaccinal preparations].[用于制备疫苗的福氏志贺氏菌菌株的质粒图谱分析]
Zh Mikrobiol Epidemiol Immunobiol. 1994 Nov-Dec(6):67-8.
7
[Nature of the genetic control of antibiotic resistance in a Pseudomonas aeruginosa BS205 strain].[铜绿假单胞菌BS205菌株抗生素抗性的遗传控制本质]
Antibiotiki. 1982 Oct;27(10):766-70.
8
[Characteristics of attenuated immunogenic mutants of shigella flexneri selected from phosphomycin-resistant clones].[从磷霉素抗性克隆中筛选出的福氏志贺氏菌减毒免疫原性突变体的特性]
Zh Mikrobiol Epidemiol Immunobiol. 1980 Jun(6):58-63.
9
[Selection of thermosensitive mutants in the streptomycin region of the Escherichia coli chromosome].[大肠杆菌染色体链霉素区域热敏突变体的筛选]
Arch Int Physiol Biochim. 1974 Feb;82(1):181.
10
Keratoconjunctivitis test in Shigella flexneri 2A hybrids obtained in a cross with different strains of E. coli K12.
Ann Inst Pasteur (Paris). 1970 Jun;118(6):761-6.